- Home
- VSTM
VSTM
Verastem Inc.
as of 01-06-2026 3:45pm EST
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 723.8M | IPO Year: | 2012 |
| Target Price: | $13.38 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.01 - $11.24 | Next Earning Date: | 11-04-2025 |
| Revenue: | $13,379,000 | Revenue Growth: | 33.79% |
| Revenue Growth (this year): | 208.54% | Revenue Growth (next year): | 251.40% |
AI-Powered VSTM Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Verastem Inc. (VSTM)
Chief Financial Officer
Avg Cost/Share
$7.86
Shares
80
Total Value
$628.80
Owned After
109,758
SEC Form 4
Director
Avg Cost/Share
$9.14
Shares
283
Total Value
$2,586.62
Owned After
41,678
SEC Form 4
Director
Avg Cost/Share
$9.14
Shares
592
Total Value
$5,410.88
Owned After
101,147
SEC Form 4
President and CEO
Avg Cost/Share
$9.14
Shares
393
Total Value
$3,592.02
Owned After
410,425
SEC Form 4
President and CEO
Avg Cost/Share
$10.25
Shares
2,000
Total Value
$20,500.00
Owned After
410,425
SEC Form 4
President and CEO
Avg Cost/Share
$10.50
Shares
2,000
Total Value
$21,000.00
Owned After
410,425
SEC Form 4
President and CEO
Avg Cost/Share
$10.61
Shares
2,000
Total Value
$21,220.00
Owned After
410,425
SEC Form 4
President and CEO
Avg Cost/Share
$10.00
Shares
2,000
Total Value
$20,000.00
Owned After
410,425
SEC Form 4
President and CEO
Avg Cost/Share
$10.00
Shares
2,000
Total Value
$20,000.00
Owned After
410,425
SEC Form 4
President and CEO
Avg Cost/Share
$10.32
Shares
2,000
Total Value
$20,640.00
Owned After
410,425
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Calkins Daniel | VSTM | Chief Financial Officer | Dec 24, 2025 | Sell | $7.86 | 80 | $628.80 | 109,758 | |
| Gagnon Robert E. | VSTM | Director | Dec 16, 2025 | Sell | $9.14 | 283 | $2,586.62 | 41,678 | |
| Stuglik Brian M | VSTM | Director | Dec 16, 2025 | Sell | $9.14 | 592 | $5,410.88 | 101,147 | |
| Paterson Dan | VSTM | President and CEO | Dec 16, 2025 | Sell | $9.14 | 393 | $3,592.02 | 410,425 | |
| Paterson Dan | VSTM | President and CEO | Dec 9, 2025 | Sell | $10.25 | 2,000 | $20,500.00 | 410,425 | |
| Paterson Dan | VSTM | President and CEO | Dec 8, 2025 | Sell | $10.50 | 2,000 | $21,000.00 | 410,425 | |
| Paterson Dan | VSTM | President and CEO | Dec 5, 2025 | Sell | $10.61 | 2,000 | $21,220.00 | 410,425 | |
| Paterson Dan | VSTM | President and CEO | Dec 4, 2025 | Sell | $10.00 | 2,000 | $20,000.00 | 410,425 | |
| Paterson Dan | VSTM | President and CEO | Dec 3, 2025 | Sell | $10.00 | 2,000 | $20,000.00 | 410,425 | |
| Paterson Dan | VSTM | President and CEO | Dec 2, 2025 | Sell | $10.32 | 2,000 | $20,640.00 | 410,425 |
Compare VSTM vs Leading Stocks
See how VSTM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.